PMID- 32998149
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20231028
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Print)
IS  - 0030-2414 (Linking)
VI  - 98
IP  - 12
DP  - 2020
TI  - Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 
      Expression with or without ERBB2 Gene Amplification.
PG  - 884-888
LID - 10.1159/000509148 [doi]
AB  - BACKGROUND: Prior studies have shown that patients whose tumor overexpresses Her2 
      at 3+ level by immunohistochemistry (IHC) fare better than those whose tumor 
      overexpresses Her2 at 2+ level (with ERBB2 amplified). Therefore, it would be 
      important to compare the outcome of patients whose tumor expresses Her2 at 2+ 
      level but further classify by gene amplification studies as positive or negative. 
      METHODS: We retrospectively identified patients with advanced gastroesophageal 
      adenocarcinoma with low Her2 protein expression (2+ by IHC) whose tumors were 
      evaluated for gene amplification of ERBB2 by fluorescence in situ hybridization 
      (FISH). All patients received first-line therapy, and trastuzu-mab was added 
      according to Her2 status. We compared overall survival (OS), progression-free 
      survival (PFS), and overall response rate (ORR) of the entire cohort and compared 
      Her2-positive tumor patients' outcomes with Her2-negative tumor patients' 
      outcomes. All patients had treatment response assessments and follow-ups at our 
      institution. RESULTS: We identified 87 patients whose tumors expressed Her2 at 2+ 
      level. 51 (58.6%) were Her2-negative and 36 (41.4%) were Her2-positive by FISH. 
      For the entire cohort, the median OS was 26 months (95% confidence interval 
      16.6-37.6), and the median PFS was 12.2 months (95% confidence interval 
      9.7-19.3). Median OS, median PFS, and ORR did not differ between Her2-positive 
      and Her2-negative patients (p = 0.70, p = 0.60, p = 0.91, respectively). 
      CONCLUSIONS: Our data suggest that patients with Her2 positivity or negativity 
      when tumors have lower Her2 protein expression (2 + by IHC) have similar clinical 
      outcomes. Further research is warranted in this cohort.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Abdelhakeem, Ahmed
AU  - Abdelhakeem A
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Wang, Xuemei
AU  - Wang X
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Rogers, Jane E
AU  - Rogers JE
AD  - Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Trail, Allison
AU  - Trail A
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Zhao, Meina
AU  - Zhao M
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Blum-Murphy, Mariela
AU  - Blum-Murphy M
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Estrella, J S
AU  - Estrella JS
AD  - Department of Anatomical Pathology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Ajani, Jaffer A
AU  - Ajani JA
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA, jajani@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA138671/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200930
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Esophageal Neoplasms/*genetics/pathology
MH  - Female
MH  - Gene Amplification/genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Oncogenes/genetics
MH  - Progression-Free Survival
MH  - Receptor, ErbB-2/*genetics
MH  - Stomach Neoplasms/*genetics/pathology
PMC - PMC10604547
MID - NIHMS1938171
OTO - NOTNLM
OT  - ERBB2
OT  - FISH
OT  - Gastroesophageal cancer
OT  - HER2
OT  - Survival
COIS- Conflict of interest: There is no relevant conflict of interest to declare by any 
      author.
EDAT- 2020/10/01 06:00
MHDA- 2020/12/15 06:00
PMCR- 2023/10/27
CRDT- 2020/09/30 20:07
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/30 20:07 [entrez]
PHST- 2023/10/27 00:00 [pmc-release]
AID - 000509148 [pii]
AID - 10.1159/000509148 [doi]
PST - ppublish
SO  - Oncology. 2020;98(12):884-888. doi: 10.1159/000509148. Epub 2020 Sep 30.